Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lessened its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULCFree Report) by 13.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 83,428 shares of the company’s stock after selling 13,000 shares during the quarter. Commonwealth Equity Services LLC owned about 0.13% of Fulcrum Therapeutics worth $788,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in Fulcrum Therapeutics by 348.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,150 shares of the company’s stock valued at $48,000 after buying an additional 5,556 shares during the period. Capstone Investment Advisors LLC purchased a new position in Fulcrum Therapeutics in the fourth quarter valued at $68,000. Citigroup Inc. grew its stake in Fulcrum Therapeutics by 1,028.5% during the 3rd quarter. Citigroup Inc. now owns 89,189 shares of the company’s stock worth $396,000 after purchasing an additional 81,286 shares in the last quarter. Affinity Asset Advisors LLC purchased a new stake in Fulcrum Therapeutics during the 4th quarter worth about $844,000. Finally, Opaleye Management Inc. acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at about $878,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Royal Bank of Canada initiated coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 target price on the stock. The Goldman Sachs Group raised shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $6.00 to $15.00 in a research report on Monday, May 13th. Oppenheimer dropped their target price on Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, May 14th. Cantor Fitzgerald assumed coverage on Fulcrum Therapeutics in a report on Monday, May 20th. They set an “overweight” rating and a $23.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Fulcrum Therapeutics has an average rating of “Buy” and a consensus price target of $15.57.

Check Out Our Latest Analysis on Fulcrum Therapeutics

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $6.53 on Wednesday. The stock’s 50-day moving average is $7.26 and its two-hundred day moving average is $8.06. Fulcrum Therapeutics, Inc. has a 1 year low of $3.14 and a 1 year high of $13.70. The firm has a market cap of $405.84 million, a price-to-earnings ratio of -4.08 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULCGet Free Report) last announced its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative return on equity of 40.60% and a negative net margin of 3,470.05%. As a group, research analysts predict that Fulcrum Therapeutics, Inc. will post -1.24 EPS for the current year.

About Fulcrum Therapeutics

(Free Report)

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

See Also

Want to see what other hedge funds are holding FULC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulcrum Therapeutics, Inc. (NASDAQ:FULCFree Report).

Institutional Ownership by Quarter for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.